3 Stocks Pushing The Health Services Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 128 points (-0.8%) at 16,374 as of Friday, April 25, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 926 issues advancing vs. 2,054 declining with 148 unchanged.

The Health Services industry currently sits down 0.9% versus the S&P 500, which is down 0.7%. On the negative front, top decliners within the industry include PerkinElmer ( PKI), down 3.4%, Intuitive Surgical ( ISRG), down 1.6%, Aetna ( AET), down 1.6%, Thermo Fisher Scientific ( TMO), down 1.1% and UnitedHealth Group ( UNH), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Covidien ( COV) is one of the companies pushing the Health Services industry lower today. As of noon trading, Covidien is down $1.82 (-2.6%) to $69.14 on heavy volume. Thus far, 3.8 million shares of Covidien exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $67.68-$69.50 after having opened the day at $69.39 as compared to the previous trading day's close of $70.96.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $31.8 billion and is part of the health care sector. Shares are up 4.2% year-to-date as of the close of trading on Thursday. Currently there are 15 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Agilent Technologies ( A) is down $0.98 (-1.8%) to $54.30 on light volume. Thus far, 829,113 shares of Agilent Technologies exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $54.26-$55.25 after having opened the day at $55.25 as compared to the previous trading day's close of $55.28.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $18.3 billion and is part of the health care sector. Shares are down 3.3% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Agilent Technologies Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Boston Scientific ( BSX) is down $0.27 (-2.0%) to $13.48 on average volume. Thus far, 4.8 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 12.0 million shares. The stock has ranged in price between $13.40-$13.72 after having opened the day at $13.72 as compared to the previous trading day's close of $13.75.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Boston Scientific has a market cap of $18.1 billion and is part of the health care sector. Shares are up 14.4% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Boston Scientific as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Boston Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback